Cintia Piccina Sells 24,531 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics plc (NASDAQ:ADAP) insider Cintia Piccina sold 24,531 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $0.93, for a total transaction of $22,813.83. Following the sale, the insider now directly owns 38,293 shares in the company, valued at $35,612.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Adaptimmune Therapeutics Stock Performance

Adaptimmune Therapeutics stock opened at $0.88 on Thursday. The company has a 50-day simple moving average of $1.08 and a 200-day simple moving average of $1.07. The firm has a market capitalization of $217.20 million, a P/E ratio of -1.19 and a beta of 2.33. Adaptimmune Therapeutics plc has a one year low of $0.42 and a one year high of $2.05.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $5.68 million for the quarter, compared to the consensus estimate of $4.40 million. Adaptimmune Therapeutics had a negative return on equity of 259.68% and a negative net margin of 890.13%. As a group, sell-side analysts forecast that Adaptimmune Therapeutics plc will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ADAP. Scotiabank began coverage on shares of Adaptimmune Therapeutics in a report on Thursday, May 30th. They set a “sector outperform” rating and a $3.15 target price on the stock. StockNews.com raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 3rd. Finally, Mizuho dropped their target price on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, May 17th.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Columbia Advisory Partners LLC bought a new position in Adaptimmune Therapeutics in the 1st quarter valued at about $25,000. JTC Employer Solutions Trustee Ltd bought a new position in Adaptimmune Therapeutics in the 1st quarter valued at about $41,000. Twin Focus Capital Partners LLC bought a new position in Adaptimmune Therapeutics in the 4th quarter valued at about $44,000. Boulder Hill Capital Management LP bought a new position in Adaptimmune Therapeutics in the 1st quarter valued at about $143,000. Finally, Harbor Capital Advisors Inc. grew its position in Adaptimmune Therapeutics by 9.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 13,317 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.